Michael R. Friedman - 15 May 2026 Form 4 Insider Report for Galera Therapeutics, Inc. (GRTX)

Reporting relationship: Director
Issuer ticker: GRTX
Reported as of: 15 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Aug 2026, 16:17:58 UTC
Prior SEC filing: 09 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ J. Mel Sorensen, Attorney-in-Fact for Michael Friedman

Key filing fact

Michael R. Friedman filed Form 4 for Galera Therapeutics, Inc. (GRTX) on 05 Aug 2026.

Key facts

This page summarizes Michael R. Friedman's Form 4 filing for Galera Therapeutics, Inc. (GRTX).
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 05 Aug 2026, 16:17.

Change

Previous filing in this sequence was filed on 09 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001993243 Primary reporting owner

FRIEDMAN MICHAEL R.

Relationship: Director
Address: C/O GALERA THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 225, MALVERN
Signature: /s/ J. Mel Sorensen, Attorney-in-Fact for Michael Friedman
Signature date: 05 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GRTX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +2,989,399
Change %: +56%
Price
Shares after: 8,326,269
Date: 15 May 2026
Ownership: See Footnote
Footnotes: F1, F2

GRTX transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -41,631
Change %: -100%
Price
Shares after: 0
Date: 03 Aug 2026
Ownership: See Footnote
Footnotes: F2, F3, F4, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GRTX transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares: -2,989
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 15 May 2026
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 2,989,399
Exercise price
Footnotes: F1, F2

GRTX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -480
Change %: -100%
Price
Shares after: 0
Date: 03 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 480
Exercise price: $8.20
Footnotes: F3, F4, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Michael R. Friedman is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 6 footnotes

Footnote F1

On February 12, 2026, Galera Therapeutics, Inc. ("Galera") filed a Certificate of Amendment (the "Amendment") to the Certificate of Designation of Preferences, Rights, and Limitations of Series B Non-Voting Convertible Preferred Stock. The Amendment provided that, in the sole discretion of Galera's board of directors, Galera may elect to convert, in whole or in part, outstanding shares of Series B Non-Voting Convertible Preferred Stock ("Series B Preferred Stock") into a number of shares of Galera common stock calculated based on the Conversion Ratio (defined as 1,000 shares of Galera common stock issuable upon the conversion of each share of Series B Preferred Stock) (a "Mandatory Conversion"). On May 15, 2026, Galera effected a Mandatory Conversion of Series B Preferred Stock, including shares of Series B Preferred Stock held by the Reporting Person. The shares of Series B Preferred Stock had no expiration date.

Footnote F2

These securities are held by Equity Trust Company, Custodian FBO Michael Friedman Roth IRA.

Footnote F3

These numbers have been adjusted to reflect the 1-for-200 reverse stock split (the "Reverse Stock Split") Galera Therapeutics, Inc. ("Galera") effected on July 12, 2026.

Footnote F4

Pursuant to an Agreement and Plan of Merger, dated as of April 14, 2026 (the "Merger Agreement"), by and among Galera, Obsidian Therapeutics, Inc. ("Obsidian"), Gazelle Parent, Inc. ("Parent"), Onyx MergerSub, Inc., a wholly owned subsidiary of Parent ("Obsidian Merger Sub"), and Gazelle Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Galera Merger Sub"), on August 3, 2026, Galera merged with and into Galera Merger Sub, with Galera surviving as a wholly owned subsidiary of Parent (the "Galera Merger"), and Obsidian merged with and into Obsidian Merger Sub, with Obsidian surviving as a wholly owned subsidiary of Parent (the "Obsidian Merger" and, together with the Galera Merger, the "Mergers").

Footnote F5

At the effective time of the Galera Merger (the "Galera Effective Time"), each outstanding share of Galera common stock (excluding any shares of Galera common stock held by stockholders who had exercised and perfected appraisal rights for such shares) was converted into the right to receive 0.7019 shares of Parent common stock (the "Galera Exchange Ratio").

Footnote F6

At the Galera Effective Time, each outstanding Galera stock option with an exercise price per share less than $15.62 (each, an "In-the-Money Option"), which was the closing trading price of a share of Galera common stock on the last full trading day on which the Galera common stock was traded prior to the date of the Galera Effective Time, became fully vested and was converted into shares of Parent common stock determined by (i) multiplying the number of shares of Galera common stock underlying the In-the-Money Option by the Galera Exchange Ratio (rounded down to the nearest whole share) then (ii) subtracting the number of shares of Parent common stock with a value equal to the exercise price and withholding taxes each required to be paid with respect to the net exercise of the In-the-Money Option, calculated pursuant to the formula set forth in Section 2.6(i) of the Merger Agreement.